ECOG-ACRIN EA6174 (Merkel Cell Carcinoma)

What is the Purpose of this Study?

If you choose to join the study you will:
-Either get the study drug, Pembrolizumab, after surgery, OR
-Be observed after surgery for up to 1 year (no study drug)
-Complete regular follow-up appointments with your doctor every 6 months for 5 years
What is the Condition Being Studied?
Stage I -IIIB Merkel Cell Carcinoma (MCC) that has been removed by surgery

Who Can Participate in this Study?

Adults with Merkel cell carcinoma (MCC).

Age Group
Adults
Participating Institutions

What is Involved?

We are doing this study to learn if we can lower the chance of your cancer growing back by adding the study drug (Pembrolizumab) after your surgery.

Study Details

Full Title
ECOG-ACRIN EA6174 STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma with Pembrolizumab - A Phase III Trial
Principal Investigator

Contacts
Melanoma and other Skin DCI Clinical Research Team
Protocol Number
IRB:
PRO00103859

NCT:
NCT03712605
ClinicalTrials.gov
View on ClinicalTrials.gov